Health AI Central
Share:
Peer-Reviewed Publication
Urol Oncol2023;41(9):369-375.September 1, 2023Journal Article

The costs and inequities of precision medicine for patients with prostate cancer: A call to action.

Meera V Ragavan1, Hala T Borno2
1Division of Hematology Oncology, Department of Medicine, University of California, San Francisco, CA. Electronic address: meera.ragavan@ucsf.edu.
2Division of Hematology Oncology, Department of Medicine, University of California, San Francisco, CA; Trial Library, Inc, San Francisco, CA.
PubMed DOI

Abstract

Financial toxicity is a growing problem in the delivery of cancer care and contributes to inequities in outcomes across the cancer care continuum. Racial/ethnic inequities in prostate cancer, the most common cancer diagnosed in men, are well described, and threaten to widen in the era of precision oncology given the numerous structural barriers to accessing novel diagnostic studies and treatments,…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.